

RANIBIZUMAB solution for injection (Lucentis®) for the treatment of proliferative diabetic retinopathy

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of RANIBIZUMAB solution for injection (Lucentis®) for the treatment of proliferative diabetic retinopathy.

GREY

Ranibizumab has been granted a license extension and is now indicated for the treatment of proliferative diabetic retinopathy.¹

- > This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, clinicians should continue to follow current guidance for the treatment of diabetic retinopathy:

- > The Royal College of Ophthalmologists; [Diabetic Retinopathy Guidelines](#), last updated July 2013.

References

1. Novartis Pharmaceuticals UK Ltd. Summary of Product Characteristics; [Lucentis 10 mg/ml solution for injection in pre-filled syringe](#), 21 October 2019. Accessed online 18 December 2019.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.